tazobactam has been researched along with glycine in 5 studies
| Studies (tazobactam) | Trials (tazobactam) | Recent Studies (post-2010) (tazobactam) | Studies (glycine) | Trials (glycine) | Recent Studies (post-2010) (glycine) |
|---|---|---|---|---|---|
| 1,327 | 153 | 694 | 35,163 | 756 | 8,415 |
| Protein | Taxonomy | tazobactam (IC50) | glycine (IC50) |
|---|---|---|---|
| Glutamate receptor ionotropic, NMDA 1 | Rattus norvegicus (Norway rat) | 1.4852 | |
| Sodium- and chloride-dependent glycine transporter 1 | Homo sapiens (human) | 106 | |
| Glutamate receptor ionotropic, NMDA 2A | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2B | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2C | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 2D | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 3B | Rattus norvegicus (Norway rat) | 0.3253 | |
| Glutamate receptor ionotropic, NMDA 3A | Rattus norvegicus (Norway rat) | 0.3253 | |
| Sodium- and chloride-dependent glycine transporter 2 | Homo sapiens (human) | 128 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Anderson, VE; Bethel, CR; Bonomo, RA; Guo, B; Helfand, MS; Hujer, AM; Jin, Z; Ng, LM; Pagan-Rodriguez, D; Simmons, R; Zhou, X | 1 |
| Bethel, CR; Bonomo, RA; Knox, JR; Sun, T | 1 |
| Bonomo, RA; Buynak, JD; Carey, PR; Helfand, MS; Taracila, MA; Totir, MA; van den Akker, F | 1 |
| Bachta, KER; Bertucci, HK; Brunzelle, JS; Gatesy, SWM; Hauser, AR; Lebrun-Corbin, M; Minasov, G; Ozer, EA; Pincus, NB; Rosas-Lemus, M; Satchell, KJF; Shuvalova, LA | 1 |
5 other study(ies) available for tazobactam and glycine
| Article | Year |
|---|---|
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Tazobactam inactivation of SHV-1 and the inhibitor-resistant Ser130 -->Gly SHV-1 beta-lactamase: insights into the mechanism of inhibition.
Topics: beta-Lactamases; Binding Sites; Crystallography, X-Ray; Enzyme Inhibitors; Glycine; Kinetics; Mass Spectrometry; Models, Chemical; Penicillanic Acid; Serine; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Tazobactam; Trypsin | 2004 |
Inhibitor-resistant class A beta-lactamases: consequences of the Ser130-to-Gly mutation seen in Apo and tazobactam structures of the SHV-1 variant.
Topics: Alanine; Amino Acid Substitution; Apoenzymes; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; Binding Sites; Catalysis; Crystallography, X-Ray; Enzyme Inhibitors; Escherichia coli Proteins; Genetic Variation; Glutamic Acid; Glycine; Hydrolysis; Models, Molecular; Mutagenesis, Site-Directed; Penicillanic Acid; Serine; Tazobactam | 2004 |
Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Clavulanic Acid; Crystallography, X-Ray; Enzyme Inhibitors; Glycine; Penicillanic Acid; Serine; Spectrum Analysis, Raman; Stereoisomerism; Tazobactam | 2007 |
Functional and Structural Characterization of OXA-935, a Novel OXA-10-Family β-Lactamase from Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aspartic Acid; Azabicyclo Compounds; beta-Lactamase Inhibitors; beta-Lactamases; Ceftazidime; Cephalosporinase; Cephalosporins; Glycine; Humans; Microbial Sensitivity Tests; Phenylalanine; Pseudomonas aeruginosa; Pseudomonas Infections; Serine; Tazobactam | 2022 |